By LE Desk
May 10: India’s Jubilant Pharma, a subsidiary of Jubilant Pharmova, announced that it has received a favourable and unanimous judgment from the United States Court of Appeals in a matter related to patent dispute with Bracco Diagnostics, summarily affirming Jubilant’s earlier favourable rulings from the US Patent Office (PTAB) and the US International Trade Commission (ITC).
These two rulings by the Appellate Court deny the appeals filed by Bracco Diagnostics, Inc (Bracco), the Business Standard reported.
Jubilant successfully challenged Bracco’s patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office as well as in a separate proceeding in the ITC. In both instances, Jubilant was successful.
Despite the rulings of both the PTAB and the ITC, Bracco filed appeals to the US Court of Appeals in Washington D.C. These appeals are now dismissed.